{
  "ticker": "IIQ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974899",
  "id": "02974899",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250731",
  "time": "0842",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06mbyrqlhlg87l.pdf",
  "summary": "### **INOVIQ Limited \u2013 Quarterly Report (Appendix 4C) \u2013 Material Information Summary**  \n\n#### **Key Operational/Clinical Highlights:**  \n- **EXO-OC ovarian cancer diagnostic test:**  \n  - Achieved **77% sensitivity (>99.6% specificity)** across all stages; **100% sensitivity for Stage I/II** (early detection).  \n  - Provisional patent filed (29 May 2025) for biomarker IP. Targeting **LDT launch late 2026, IVD kit by 2028**.  \n- **CAR-exosome therapeutics:**  \n  - **88% cell death** in triple-negative breast cancer (TNBC) and NSCLC cells in vitro. **In vivo TNBC mice model data expected 4Q 2025**.  \n- **EXO-NET commercial progress:**  \n  - Customer base grew to **60** (from 55); repeat orders from Pharma/biotech segments. Second Promega order delivered/payment received.  \n\n#### **Financials (AUD):**  \n- **Cash balance (30 June 2025): $6.5m** (vs. $8.0m prior quarter).  \n- **Net operating cash outflow: $1.44m** (R&D spend: $822k).  \n- **Estimated funding runway: 4.5 quarters** at current burn.  \n\n#### **Capital Markets Implications:**  \n- **No capital raising announced**, but liquidity tightens (~4.5 quarters of cash).  \n- **Share price pressure noted** due to fund manager redemptions; management anticipates recovery.  \n\n**Materiality Focus:** Clinical milestones (EXO-OC validation, CAR-exosome efficacy) dominate; financials show constrained but sufficient liquidity.",
  "usage": {
    "prompt_tokens": 5936,
    "completion_tokens": 357,
    "total_tokens": 6293,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-30T22:52:54.971401"
}